These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36378498)

  • 1. Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.
    Iacucci M; Jeffery L; Acharjee A; Grisan E; Buda A; Nardone OM; Smith SCL; Labarile N; Zardo D; Ungar B; Hunter S; Mao R; Cannatelli R; Shivaji UN; Parigi TL; Reynolds GM; Gkoutos GV; Ghosh S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1409-1420. PubMed ID: 36378498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
    Loly JP; Vieujean S; Reenaers C; Van Kemseke C; Seidel ScD L; Louis E; Somja J
    Inflamm Bowel Dis; 2024 Feb; 30(2):240-246. PubMed ID: 37042951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
    Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
    EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
    Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
    Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of confocal laser endomicroscopy for assessment and monitoring of therapeutic response in patients with inflammatory bowel disease.
    Karstensen JG
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ultra-high definition endoscopy (endomicroscopy and endocytoscopy) and real-time histologic examination in inflammatory bowel disease: Scoping review.
    Pal P; Ramchandani M; Patel R; Banerjee R; Kanaganti S; Gupta R; Tandan M; Reddy DN
    Dig Endosc; 2024 Mar; 36(3):274-289. PubMed ID: 37573562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
    Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
    Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index.
    Rahmi G; Coron E; Perrod G; Levy M; Moreau J; Moussata D; Perez-Cuadrado-Robles E; Chupin A; Quénéhervé L; Bourreille A; Marchal A; Cellier C; Peyrin-Biroulet L
    J Crohns Colitis; 2021 Jun; 15(6):994-999. PubMed ID: 33336249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
    Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.